Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 19 to consider how cardiovascular outcomes data on fenofibrate use in combination with simvastatin relate to the efficacy and safety of Trilipix, Abbott's second-generation fenofibrate product.

You may also be interested in...



Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.

Trilipix CV Outcomes Study To Focus On Patients With High Triglycerides, Low HDL-Cholesterol

FDA follows its advisory committee’s recommendation and requires a post-marketing study of Abbott’s fibrate to determine whether combination use with a statin provides a cardiovascular benefit over statin monotherapy in high-risk patients.

Could ACCORD Results Mean Another Trial For Trilipix?

Advisory committee says data inconclusive with subgroups and recommended another study to determine if there is increased risk in women and/or benefit for high TG, low HDL-C patients.

Related Content

Topics

UsernamePublicRestriction

Register

PS072149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel